Menopausal hormone therapy has long carried a boxed warning (formerly a "black box warning") that may not accurately reflect the therapy's risk-benefit profile for all patients. This course discusses the FDA's recent removal of boxed warnings for select hormone therapy (HT) products, the rationale for this change, and how evolving guidance may impact patient care. You will explore strategies to support evidence-based counseling and individualized decision-making for patients considering HT.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Erin Raney, PharmD
Professor
Midwestern University College of Pharmacy

GAMECHANGERS CLINICAL UPDATE SERIES
The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. 

PRACTICE RESOURCE
Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. 

 CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize the FDA's updated position on boxed warnings for menopausal hormone therapy.
2. Identify key considerations for pharmacists when counseling patients about the benefits and risks of hormone therapy.

Rachel Maynard and Erin Raney have no relevant financial relationships with ineligible companies to disclose.

0.075 CEU/0.75 Hr
UAN: 0107-0000-26-044-H01-P
Initial release date: 1/26/2026
Expiration date: 1/26/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Follow CEimpact on Social Media:
LinkedIn
Instagram

Ranitidine — once withdrawn from the market over safety concerns — was recently re‑approved by the FDA in a reformulated version, raising important questions for pharmacists and patients alike. This course outlines the FDA’s recent approval, reviews the reformulated product's changes (including manufacturing and labeling), and examines practical considerations for dispensing, counseling, and patient safety. You will gain clarity on when ranitidine may be appropriate for use (again) and how to guide patients confidently in its safe use.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
K. Ashley Garling-Nanez, PharmD
Assistant Director of Program
UT Center of Health Communications

GAMECHANGERS CLINICAL UPDATE SERIES
The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. 

PRACTICE RESOURCE
Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase the Clinical Update Series and claim your CPE credit, click here.

 CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize the major safety and regulatory issues that prompted ranitidine's withdrawal, and the changes made in the reformulated product approved in 2025.
2. Describe pharmacist‑relevant considerations for dispensing, patient counseling, and transition from alternative acid‑reducing therapies.

Rachel Maynard and K. Ashley Garling-Nanez have no relevant financial relationships with ineligible companies to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-043-H01-P
Initial release date: 1/19/2026
Expiration date: 1/19/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Recent years have seen a troubling resurgence of whooping cough and measles — diseases many thought were largely controlled — highlighting the continuing importance of vaccination, surveillance, and community education. This course reviews the latest evidence on global and local trends, explores the factors driving renewed outbreaks, and discusses the key roles of pharmacists in prevention and early detection. You will gain insights to be better prepared to support immunization efforts, patient counseling, and public health awareness in response to this resurgence.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Christina O'Connor, PharmD, BCPS, BCIDP
Clinical Pharmacy Manager
Mayo Clinic

GAMECHANGERS CLINICAL UPDATE SERIES
The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. 

PRACTICE RESOURCE
Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase the Clinical Update Series and claim your CPE credit, click here.

 CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe recent epidemiologic trends in pertussis and measles resurgence and factors contributing to increased incidence.
2. Identify the pharmacist's responsibilities for promoting vaccination, encouraging timely immunization, supporting outbreak prevention, and providing patient education.

Rachel Maynard and Christina O'Connor have no relevant financial relationships to disclose.

0.075 CEU/0.75 Hr
UAN: 0107-0000-26-038-H01-P
Initial release date: 1/12/2026
Expiration date: 1/12/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Corticosteroids in the treatment of community-acquired pneumonia (CAP) remain a topic of clinical curiosity and mixed opinions. In this unique episode, two expert guests share opposing perspectives—one advocating for corticosteroid use in CAP and the other urging caution—offering pharmacists a balanced view of the current evidence and practice considerations. Tune in to explore both sides of the debate and walk away with insights to inform your role in collaborative patient care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUESTS
Sam Markle, PharmD
Critical Care Pharmacist
Sanford Health

Tristan Houle, PharmD
PGY2 Critical Care Pharmacy Resident
Sanford Health

PRACTICE RESOURCE
Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe current evidence supporting and challenging the use of corticosteroids in the treatment of community-acquired pneumonia (CAP).
2. Identify key considerations for pharmacists when evaluating corticosteroid use as adjunctive therapy in CAP.

Rachel Maynard, Sam Markle, and Tristan Houle have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-032-H01-P
Initial release date: 1/5/2026
Expiration date: 1/5/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

As cannabis becomes more widely available and socially accepted, so does the misconception that it's safe to use during pregnancy and lactation. This course reviews updated guidance from the American College of Obstetricians and Gynecologists (ACOG), highlighting the evidence behind the risks and outlining how pharmacists can address misinformation and counsel patients effectively. You will learn how to support safe, informed decision-making that promotes the health of both parent and child.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Kevin Shea, PharmD
Pharmacist 
Vytal Options 

PRACTICE RESOURCE
Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Identify current ACOG recommendations regarding cannabis use during pregnancy and lactation.
2. Describe pharmacist strategies for screening, counseling, and reducing risks associated with cannabis use during the perinatal period.

Rachel Maynard and Kevin Shea have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-377-H01-P
Initial release date: 12/29/2025
Expiration date: 12/29/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Recent preclinical studies highlight the potential of micro‑dosed lithium to modulate Alzheimer’s disease pathology and support neuronal health. This episode examines the molecular mechanisms, current evidence in Alzheimer’s models, and emerging considerations for safe use and monitoring. You will gain insights to navigate this evolving topic and support informed discussions around lithium micro‑dosing in Alzheimer’s care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Dawn Gerber, PharmD, BCGP, FASCP, FAzPA, CPAFH
Professor of Pharmacy Practice
Midwestern University

PRACTICE RESOURCE
Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe current evidence on the use of microdose lithium in Alzheimer's disease.
2. Identify pharmacist considerations for monitoring, patient selection, and safety in the context of lithium micro-dosing for Alzheimer's.

Rachel Maynard and Dawn Gerber have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-375-H01-P
Initial release date: 12/22/2025
Expiration date: 12/22/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Amanda (Mandy) Mullins, PharmD, BCPS
Clinical Pharmacist Practitioner
Veterans Affairs

PRACTICE RESOURCE
Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast

CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.
2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.

Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose. 

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-371-H01-P
Initial release date: 12/15/2025
Expiration date: 12/15/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

Hunter O. Rondeau, PharmD, BCIDP, AAHIVP
Antimicrobial Stewardship Coordinator, SSM Health
Adjunct Clinical Assistant Professor, University of Kansas School of Pharmacy

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. 

Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.
 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here.

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.
2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-372-H01-P
Initial release date: 12/8/2025
Expiration date: 12/8/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Recent FDA actions have brought renewed attention to leucovorin as a potential treatment for managing symptoms associated with autism spectrum disorder. This course explores the clinical distinctions between autism and cerebral folate deficiency, reviews key evidence behind leucovorin use, and outlines counseling considerations relevant to pharmacy practice. You will gain clarity on this complex and evolving topic to better support informed, evidence-based care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Geoff Wall, PharmD, FCCP, BCPS
Professor of Pharmacy Practice
Iowa Methodist Medical Center

Rachel Maynard and Geoff Wall have no relevant financial relationships to disclose.
 
 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe current clinical evidence related to the use of leucovorin in autism and cerebral folate deficiency.
2. Identify key counseling considerations for pharmacists discussing leucovorin therapy with patients and caregivers.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-363-H01-P
Initial release date: 12/1/2025
Expiration date: 12/1/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Hunter Rondeau, PharmD, BCIDP, AAHIVP
Antimicrobial Stewardship Coordinator
SSM Health

Joshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose. 

Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated. 

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Identify newly FDA-approved antibiotics and their clinical indications.
2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-362-H01-P
Initial release date: 11/24/2025
Expiration date: 11/24/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram